Skip to main content
BAX logo

Baxter International Inc. (BAX) Stock: Price, Forecast & Analyst Target

Baxter International Inc. (BAX) — MoonshotScore 57/100 (Fair band), calculated Nov 18, 2026. Price $25.39 (-2.94%), as of the Nov 19, 2026 trading session; market cap $13.1B. Expected results Feb 11, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$25.39 −$0.77 (-2.94%) Market Cap $13.1B

Baxter International Inc. · BAX · NYSE · Healthcare · Medical - Instruments & Supplies

Research dated 2026-09-13: Baxter sells infusion, medication-delivery, surgical, organ-support and connected-care products across hospitals and other care settings. The case now rests on whether recovering operating performance and cash generation can persist while a heavy debt load limits financial flexibility.

Price as of Nov 19, 2026

Key Statistics

57 of 100

MoonshotScore v2 · Baxter International (BAX)

Fair
Business Quality Solid (62)
Financial Safety Fragile (14)
Valuation Fair (60)
Growth Durability Fading (27)
Momentum Surging (88)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Strong price action running well ahead of the business — a fragile balance sheet underneath; a move to treat with suspicion, not chase. Business Quality: Solid; Financial Safety: Fragile; Valuation: Fair; Growth Durability: Fading; Momentum: Surging.

  • EPS beat 6 of the last 8 reports
  • expected results Feb 11, 2027
  • Altman Z 2.43 · Piotroski F 4

Holding back: balance-sheet strain, soft growth

Helping: positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for BAX (57 recorded, newest six shown)
RecordedScoreBand
56Fair
56Fair
56Fair
56Fair
57Fair
57Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$25.39
Change on the day-2.94%
52-week range$15.73–$30.00
Market capitalisation$13.1B—
Price / earnings (trailing)8.31
Shares traded on the day4.67M
Beta (volatility vs the S&P 500)0.67

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $16, high $28, latest $25. $28 $16 high $28 Oct 17, 2025 Nov 19, 2026 · $25 $23Oct 17, 2025$18Oct 31, 2025$18Nov 14, 2025$19Nov 28, 2025$19Dec 12, 2025$19Dec 26, 2025$21Jan 9, 2026$20Jan 23, 2026$22Feb 6, 2026$22Feb 20, 2026$18Mar 6, 2026$16Mar 20, 2026$17Apr 2, 2026$19Apr 17, 2026$17May 1, 2026$17May 15, 2026$19May 29, 2026$21Jun 12, 2026$22Jun 26, 2026$23Jul 10, 2026$22Jul 24, 2026$28Aug 7, 2026$26Aug 21, 2026$26Sep 4, 2026$23Sep 18, 2026$23Oct 2, 2026$25Oct 16, 2026$23Oct 30, 2026$26Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Baxter International (BAX): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Negative
Valuation Moderate
Growth Durability Weak
Momentum Strong

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Negative
ROE Negative
Gross Margin Neutral

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Baxter International (BAX), and what does it report?

Short answer · as of

Baxter is not simply an instrument maker. Its revenue comes from pharmaceuticals, recurring medical supplies and therapies, capital equipment, connected devices, software and contracted services used across acute care, outpatient facilities and supervised home care.

The reporting structure separates Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. Medical Products and Therapies contributes the most revenue, making treatment volumes and demand for associated supplies especially important to the consolidated result.

2 · Latest results

What do the latest results show for Baxter International (BAX)?

The latest period brought a sequential rise in revenue, gross profit and operating profit, while the company returned to positive net income after a loss. Reported revenue and adjusted earnings also exceeded expectations, extending the improvement seen in the preceding report.

Management attributes the expected continuation of margin recovery to higher volumes, operating leverage, cost-structure actions and the passage of higher-cost inventory through the business. That explanation remains a forward operating claim; the reported improvement establishes progress, but not yet durability.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$2.83B-$46M-$0.09 (diluted)
Q4 FY2025$2.97B-$1.13B-$2.19 (diluted)
Q1 FY2026$2.70B-$15M-$0.03 (diluted)
Q2 FY2026$2.96B$126M$0.24 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Baxter International (BAX)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Operating cash flow has remained positive through the latest reported periods, and the cash balance has rebuilt from its earlier low. Capital spending rose sharply in the latest period, however, leaving substantially less cash after investment than the operating cash figure alone suggests.

Debt remains far above cash and short-term investments, producing a sizable net-debt position. Negative trailing profitability and middling distress and quality screens reinforce the risk that any relapse in margins or cash conversion would make the balance sheet more restrictive.

4 · What to check next?

What should you watch next at Baxter International (BAX)?

Short answer · as of

The next earnings report is expected on Feb 11, 2027.

Watch whether revenue holds near its recent level while gross and operating profit continue to recover. The most useful confirmation would be margin expansion accompanied by stronger cash remaining after capital spending, rather than an earnings improvement that fails to convert into cash.

Management has tied later-year improvement to volume, operating leverage, cost actions and lower pressure from higher-cost inventory. The scheduled earnings release will test that mechanism against analyst expectations, while recent leadership and material-agreement filings deserve attention for any effect on execution.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Baxter International compare with its peers?

Short answer

Baxter International's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Baxter combines pharmaceuticals and disposable therapy products with pumps, monitoring systems, surgical infrastructure, software and services. A narrower device company depends mainly on equipment placements, while Baxter can participate in the treatment itself, the supplies consumed during care and the systems used to coordinate it.

That breadth also couples Baxter to several operating demands at once: hospital procedure activity, medication use, critical-care intensity, equipment purchasing and supply-chain execution. Medical Products and Therapies remains the dominant reported business, so the portfolio is diversified without being evenly balanced.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
ResMed Inc. (RMD) Same industry, near in market value$242.61 Nov 18, 2026$34.1B95 5-pillar Nov 18, 2026
West Pharmaceutical Services, Inc. (WST) Same industry, near in market value$404.02 Nov 18, 2026$28.1B92 5-pillar Nov 18, 2026
Qiagen N.V. (QGEN) Named competitor$49.63 Nov 19, 2026$10.3B83 5-pillar Nov 18, 2026
Haemonetics Corporation (HAE) Same industry, near in market value$120.37 Nov 19, 2026$5.48B83 5-pillar Nov 18, 2026
Merit Medical Systems, Inc. (MMSI) Same industry, near in market value$84.41 Nov 19, 2026$5.06B81 5-pillar Nov 18, 2026
Alcon Inc. (ALC) Same industry, near in market value$74.52 Nov 19, 2026$35.8B80 5-pillar Nov 18, 2026
AptarGroup, Inc. (ATR) Named competitor$140.34 Nov 19, 2026$8.90B77 5-pillar Nov 18, 2026
DaVita Inc. (DVA) Named competitor$156.24 Nov 19, 2026$9.83B76 5-pillar Nov 18, 2026
Repligen Corporation (RGEN) Same industry, near in market value$170.29 Nov 19, 2026$10.9B71 5-pillar Nov 18, 2026
Avantor, Inc. (AVTR) Same industry, near in market value$15.12 Nov 19, 2026$10.3B71 5-pillar Nov 18, 2026
Teleflex Incorporated (TFX) Same industry, near in market value$163.40 Nov 19, 2026$6.48B61 5-pillar Nov 18, 2026
Baxter International (BAX) — this page$25.39$13.1B57
The Cooper Companies, Inc. (COO) Same industry, near in market value$60.33 Nov 19, 2026$11.5B40 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$20.00 – $28.00
Consensus target
$23.83
Median target
$24.50

Consensus record · Captured .

Measured against a quoted price of $25.39 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 2, 2026

Transactions
3
Identified insiders
3
Purchases
0
Sales
0
Other transactions
3

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held BAX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported BAX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Baxter International (BAX)?

Read these with our analysis →

What Investors Ask About Baxter International (BAX) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

How dependent is Baxter on Medical Products and Therapies?

Medical Products and Therapies is Baxter's largest reported revenue contributor. Performance therefore remains especially sensitive to demand for infusion, nutrition, renal-support and related treatment products, even though pharmaceuticals and healthcare systems broaden the revenue base.

What does Baxter's connected-care portfolio add beyond medical supplies?

Baxter combines patient monitoring and diagnostic technologies with devices, software and communication systems. This gives the company exposure to clinical workflows and hospital technology spending alongside demand for products consumed during treatment.

Why are Baxter's reported earnings volatile despite annual revenue growth?

Annual revenue has risen while net results have moved between substantial profits and losses, showing that sales direction alone has not determined shareholder earnings. Recent periods show operating profitability recovering from a severe loss, but the record remains uneven.

What would validate Baxter's margin expansion plan?

Higher treatment volumes should produce better operating leverage while cost actions and higher-cost inventory pressure recede. Confirmation would appear in sustained gross and operating profit improvement together with healthier cash after capital spending.

What is the BAX stock price today?

The last price recorded for Baxter International Inc. (BAX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the BAX price target?

The analyst consensus price target for Baxter International Inc. (BAX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Management outlook — dated call excerpts
  • 1. What is Baxter International (BAX), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment
  • 2. What do the latest results show for Baxter International (BAX)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Most recent periodic reports
  • 3. What are the financial strengths and risks for Baxter International (BAX)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Trailing twelve-month ratio set; Distress and quality screens; Annual revenue and net result (USD millions)
  • 4. What should you watch next at Baxter International (BAX)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Next earnings report; Analyst revenue and earnings estimates (average); Management outlook — dated call excerpts; Recent SEC filings; Most recent periodic reports
  • 5. How does Baxter International compare with its peers?: Sector / industry (provider taxonomy); Business description; Revenue by segment
  • FAQ: How dependent is Baxter on Medical Products and Therapies?: Business description; Revenue by segment
  • FAQ: What does Baxter's connected-care portfolio add beyond medical supplies?: Business description; Revenue by segment
  • FAQ: Why are Baxter's reported earnings volatile despite annual revenue growth?: Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Trailing twelve-month ratio set
  • FAQ: What would validate Baxter's margin expansion plan?: Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.